Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

T.S.K. Mok; K. Nakagawa; K. Park; Y. Ohe; N. Girard; H.R. Kim; Y-L. Wu; J. Gainor; S-H. Lee; C-H. Chiu; K. Sang-We; Y. Cheng-Ta; W. Liang; L. Wu; M-C. Lin; J. Samol; X. Zhang; J. Sylvester; S. Li; J.C-H. Yang

doi:10.1016/j.annonc.2022.10.350

YUHSpace

BROWSE

0 174

Cited 0 times in

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

Authors: T.S.K. Mok ; K. Nakagawa ; K. Park ; Y. Ohe ; N. Girard ; H.R. Kim ; Y-L. Wu ; J. Gainor ; S-H. Lee ; C-H. Chiu ; K. Sang-We ; Y. Cheng-Ta ; W. Liang ; L. Wu ; M-C. Lin ; J. Samol ; X. Zhang ; J. Sylvester ; S. Li ; J.C-H. Yang